The role of exogenous LH supplementation in ovarian stimulation is a matter of debate. Here we evaluate the impact of exogenous LH on oocyte yield and developmental competence in an oocyte donation programme. METHODS: Oocyte donors were randomized (computer-generated randomization list) to groups stimulated with FSH alone or with a combination of FSH and LH after pituitary down-regulation with a GnRH agonist administered in the mid-luteal phase. RESULTS: In donors with deep suppression of pituitary LH (<1 IU/l) before the beginning of ovarian stimulation, the inclusion of exogenous LH resulted in an increase in the number of mature oocytes and good-quality zygotes and embryos as well as higher implantation rates when compared with stimulation with FSH alone. In contrast, the inclusion of exogenous LH in the stimulation of donors with pre-stimulation serum LH of ≥1 IU/l impaired embryo morphology and lowered the implantation rate, although it increased the number of metaphase II oocytes. CONCLUSIONS: The inclusion of exogenous LH to the ovarian stimulation protocol can have beneficial or detrimental effects on oocyte yield and quality, depending on the level of endogenous LH. These data support the concept of a 'window' for LH requirement in ovarian stimulation.
Introduction
Pituitary down-regulation with a GnRH agonist is commonly used in current ovarian stimulation protocols before the beginning of exogeneous gonadotrophin administration (Hughes et al., 1992) . According to the type, dose and method of administration of GnRH agonist preparation used, this treatment leads to variable suppression of pituitary FSH and LH secretion (Westergaard et al., 2001) . At the same time, the progressive abandoning of hMG preparations, containing nearly equal activities of FSH and LH, in favour of highpurity urinary FSH preparations or recombinant FSH (rFSH) preparations further contributes to the reduction of serum LH concentration in women undergoing ovarian stimulation.
The actual importance of LH during ovarian stimulation is a matter of debate. Some authors have reported lower estradiol (E 2 ) biosynthesis (Fleming et al., 1996; Westergaard et al., 1996; De Placido et al., 2001) , lower oocyte and embryo yield (Fleming et al., 2000; De Placido et al., 2001 ) and a higher frequency of early pregnancy wastage (Westergaard et al., 2000) in normogonadotrophic women down-regulated with a GnRH agonist and stimulated with highly pure FSH prepara-tions when compared with women stimulated with hMG or with a combination of hMG and FSH. However, other authors failed to detect any relationship between serum LH levels and ovarian stimulation outcomes (Balasch et al., 2001) . Reflecting this conceptual confusion, some authors advocate the addition of hormone preparations containing LH activity to ovarian stimulation protocols if serum LH activity falls below a certain threshold level (Filicori et al., , 2001 , whereas others do not recommend any additional exogenous LH supplementation (Balasch et al., 2001) .
There may be several reasons for these discrepancies. First, individual studies differ as to the definition of the threshold serum LH level below which exogenous LH supplementation is considered. Further, LH may affect IVF results both by determining oocyte quality and by influencing uterine receptivity via ovarian secretion of E 2 or through direct effects on endometrium, myometrium, and uterine artery and vein (Rao, 2001; Shemesh, 2001) .
This prospective, randomized study was designed to address the question of LH effect on oocyte yield and quality, independently of extragonadal LH actions. To this goal, this study was performed in a group of young, normogonadotrophic oocyte donors. Embryos resulting from the donated oocytes were transferred to patients, all of whom received the same treatment to prepare the uterus for implantation, thus avoiding the possible influence of LH on uterine receptivity. Within the group of oocyte donors, the effects of exogenously administered LH are related to the degree of endogenous LH suppression.
Materials and methods

Participants
This study involved 253 oocyte donors and 506 infertile couples participating in our oocyte donation programme. The age of the oocyte donors ranged between 21-28 years. All of them were healthy volunteers with normal pituitary and ovarian function.
The age of the male patients ranged between 28-62 years, and that of the female patients ranged between 33-50 years. Each oocyte donor was involved only once in this study, and the oocytes obtained from each donor were shared between two infertile couples. The choice of oocyte donor for each infertile couple was made merely on the basis of physical resemblance between the donor and the patient. Accordingly, donor oocytes were distributed among different couples at random with regard to male and female age and the status of the reproductive function.
The indications for oocyte donation were premature or physiological menopause without spontaneous cycle (n ϭ 302), pre-menopausal with poor ovarian response in previous ovarian stimulation attempts (n ϭ 198) and repeated unexplained failures of assisted reproduction attempts that were believed to be of oocyte origin (n ϭ 6). Out of the 506 male partners of the female patients involved in this study, 290 were normozoospermic according to the World Health Organization criteria (World Health Organization, 1992) . Spermogram and spermocytogram values were moderately impaired in 156 and severely impaired in 60 of these men. Cases of azoospermia, requiring the recourse to testicular biopsy to obtain sperm, are not included in this study.
Study design and ovarian stimulation
All patients receiving embryos resulting from donated oocytes were prepared in the same way (see below). Oocyte donors were downregulated with triptorelin (Decapeptyl 3.75 mg; Ipsen Pharma, Barcelona, Spain) administered on cycle day 24. They received oral norethisterone (Primolut Nor; Shering, Madrid, Spain), 10 mg/day between cycle days 21 and 27 to reduce the risk of ovarian cyst formation in response to triptorelin. After menstrual bleeding the achievement of pituitary down-regulation was assessed by determination of serum E 2 concentration (Ͻ45 pg/ml) and by vaginal ultrasonography (absence of follicles and cysts of Ͼ10 mm in diameter). The donors were kept in the down-regulated state until the down-regulation of the respective oocyte recipients was achieved. At that time ovarian stimulation was started. The time between the menstrual bleeding following triptorelin administration and the beginning of ovarian stimulation ranged between 2 and 12 days.
One to three days before the beginning of ovarian stimulation, serum LH level was determined with the use of a commercial enzyme immunoassay kit (Vidas LH; BioMérieux, Lyon, France). The detection limit and the inter-assay coefficient of variation were 0.05 IU/l and 3.2%, respectively. The intra-assay coefficient of variation was Ͻ4.5% in the range of LH concentrations measured in this study. Oocyte donors with LH Ͻ1 IU/l were allocated at random to two groups (group I or group II) using a computer-generated randomization list. Donors allocated to 3130 group I were stimulated with FSH alone, whereas those allocated to group II received additional LH during the stimulation period. Donors with LH ജ1 IU/l were also randomized to two groups to be stimulated with FSH alone (group III) or a combination of FSH and LH (group IV).
During the first 4 days of ovarian stimulation, all oocyte donors received the same treatment. It consisted of s.c. administration of 150 IU rFSH (Puregon; Organon, Oss, The Netherlands) on days 1 and 2 of stimulation and 100 IU rFSH (Puregon) on days 3 and 4 of stimulation. On day 5 of stimulation, serum E 2 and LH levels were determined, and the number and size of ovarian follicles were evaluated by vaginal ultrasonography. The daily injections of FSH during the whole period of ovarian stimulation were administered between 18.00 h and 20.00 h, whereas blood samples for determination of E 2 and LH were taken between 9.00 h and 11.00 h on the corresponding days of stimulation.
On day 5, the stimulation protocol was adapted as follows ( Figure 1 ). In group I ovarian stimulation was continued with FSH alone, whereas donors allocated to group II received exogenous LH, in addition to FSH, on days 5-7 of stimulation (Figure 1 ). This treatment was realised by daily injection of 1 vial of hMG (Menogon; Langley, Berkshire, UK), containing 75 IU of FSH and 75 IU of LH activity, on these days. In addition, both group I and group II were subdivided on day 5 of stimulation according to serum E 2 concentration (Figure 1 ). If serum E 2 was Ͻ100 pg/ml (groups Ia and IIa), the daily dose of FSH was increased by adding 75 IU of urinary FSH (uFSH) on days 5-7. In group IIa this additional FSH was contained in the hMG preparation (Menogon) added on these days, whereas the corresponding dose increase in group Ia was realised by adding 75 IU of purified uFSH (Neofertinorm; Serono, Rome, Italy). If serum E 2 on day 5 of stimulation was ജ100 pg/ml (groups Ib and IIb), the dose of rFSH was lowered to 50 IU/day, while 75 IU uFSH was added in the form of Neofertinorm (Serono) or Menogon (Ferring) in groups Ib and IIb respectively (Figure 1) .
In groups III and IV the same dose adaptation was made on day 5 of stimulation ( Figure 2 ). Hence each of these groups was split into two, the serum concentration of E 2 measured on day 5 of stimulation being Ͻ100 pg/ml in groups IIIa and IVa and ജ100 pg/ml in groups IIIb and IVb.
This design was chosen to facilitate comparisons between groups with similar early response to ovarian stimulation in terms of E 2 secretion but with different initial serum LH level (group Ia versus group IIIa; group Ib versus group IIIb), between groups with similarly low initial levels of serum LH and similar initial response to ovarian stimulation receiving or not receiving exogeneous LH during a later phase of stimulation (group Ia versus group IIa; group Ib versus group IIb) and between groups with relatively high initial serum LH levels and similar initial response to ovarian stimulation receiving or not receiving exogeneous LH during a later phase of stimulation (group IIIa versus group IVa; group IIIb versus IVb).
Beginning with day 8 of stimulation, the dose of rFSH administered to oocyte donors became group-independent (Figures 1 and 2) and was adapted to the individual increase in serum E 2 level and the number and size of ovarian follicles determined by vaginal ultrasonography. Both measurements were performed every other day. In addition, donors in groups I and III continued to receive the daily dose of 75 IU of uFSH (Neofertinorm), while donors in groups II and IV received 1 vial of Menogon (75 IU of uFSH and 75 IU of LH).
Ovarian puncture was performed on day 14 of stimulation, in phase with the protocol of the corresponding oocyte recipient preparation (see below). Ovulation was induced by i.m. injection of 10 000 IU of HCG (Profasi, Serono, Rome, Italy) 36 h before ovarian puncture. All donors involved in this study had ജ5 follicles of Ͼ18 mm in diameter on the day of HCG administration.
Oocyte recipient preparation
Patients who still had spontaneous menstrual bleeding were first subjected to pituitary down-regulation with a long-acting GnRH agonist preparation (triptorelin; Decapeptyl 3.75 mg; Ipsen Pharma), administered between days 21-28 of the cycle. The day of triptorelin administration was determined taking into account the date of the patient's last menstrual bleeding, the planned date of embryo transfer and the usual duration of the patient's menstrual cycle. To reduce the risk of ovarian cyst formation in response to the GnRH agonist, patients either took a contraceptive pill during the cycle in which GnRH agonist was administered or were given oral norethisterone (Primolut Nor), 10 mg daily, for 7 days beginning 3 days before, and 3131 ending 3 days after, the application of GnRH agonist. Patients who lacked spontaneous menstrual bleeding were given a contraceptive pill (Ovanon; Organon, Puteaux, France) for at least one cycle prior to commencing endometrial preparation for embryo transfer.
Endometrium growth was stimulated by progressively increasing daily doses of orally administered estradiol valerate (Progynova; Schering) followed by vaginally administered natural micronized progesterone (Utrogestan; Laboratoires Besins-Iscovesco, Paris, France). Details of these treatments have been published earlier (Tesarik et al., 2002) . The time between the administration of GnRH agonist and the beginning of endometrial growth stimulation ranged between 12 and 26 days.
Assisted reproduction techniques
Oocyte-cumulus complexes were incubated for 2-4 h in IVF-50 medium (Vitrolife; Göteborg, Sweden) equilibrated with 5% CO 2 in air before performing ICSI. Shortly before ICSI the cumulus oophorus and the corona radiata were removed from the oocytes by incubation with 20 IU/l hyaluronidase (Hyase; Vitrolife) solution prepared with equilibrated Gamete 100 medium (Vitrolife). The incubation was carried out at 37°C for 20-30 s.
Within 1 h following the cumulus oophorus and corona radiata removal, oocytes were subjected to ICSI using previously described techniques and instruments (Tesarik and Sousa, 1995) . Fertilization outcomes were evaluated by a single observation of the oocytes 15-16 h after ICSI. Oocytes were considered to be normally fertilized when they showed 2 pronuclei (PN) and 2 polar bodies (PB) at that time. The numbers of abnormally fertilized/activated oocytes (1 PN and 2 PB or Ͼ2 PN with 1 or 2 PB) and of oocytes that failed to be activated (metaphase II) were also noted.
Normally fertilized oocytes were incubated further at 37°C in IVF-50 medium (Vitrolife) equilibrated with 5% CO 2 in air as described (Tesarik et al., 2002) . On day 3, 2-4 embryos with the best morphological grade (see below) were selected and transferred to the patient's uterus. Only embryos graded as excellent or good were transferred in all treatment attempts. The remaining embryos were cryopreserved. This study only involves data obtained with fresh embryo transfers.
After embryo transfer, the patients were given oral estradiol valerate (Progynova; 4 mg/day), aspirin (Bayer, Madrid, Spain, 100 mg/day), and vaginally administered natural micronized progesterone (Utrogestan; Laboratoires Besins-Iscovesco, 600 mg/day). Pregnancy was assessed 12 days after embryo transfer by determining serum β-HCG concentration. In case of pregnancy the treatment with estradiol valerate and aspirin was continued up to the end of the third week after embryo transfer, and the treatment with progesterone was prolonged until the end of the third month after transfer.
Pronuclear zygote and cleaving embryo grading
Normally fertilized, two-pronucleated zygotes were evaluated within an interval of 15-16 h after ICSI using previously described scoring criteria (Tesarik and Greco, 1999) . The scoring system was simplified by grouping all abnormal pronuclear patterns into a single group as described earlier (Tesarik et al., 2000) .
Cleaving embryos were graded on day 3 after ICSI using criteria based on the cleavage speed and morphology (blastomere regularity and the volume occupied by anucleate cell fragments). The latter was quantified with the used of previously described embryo morphologygrading criteria (Bolton et al., 1989) . The original grades 1-4 are presented as excellent, good, fair and poor respectively.
Statistics
Means were compared by ANOVA and paired Student's t-test. Proportions were compared by χ 2 -test. All statistics were performed using StatView II statistical package (Abacus Concepts, Berkeley, California, USA). Unless stated otherwise, values are considered as significantly different if P Ͻ 0.05.
Results
Evaluation of group homogeneity
No differences were found between individual groups (Table I) when treatment attempts using oocytes from donors forming 3132 different groups, according to the study design, were compared using the following: oocyte donor and recipient age; the time that donors were kept in the down-regulated state; the proportion of recipients in whom pituitary down-regulation with GnRH agonist was required; the time from the oocyte recipient's last menstrual period to embryo transfer; the recipient's endometrial thickness on the day of embryo transfer; and the number of embryos transferred. The groups can thus be considered as homogeneous with regard to basic features of treatment attempts other than those according to which individual groups were defined.
Basic characteristics of ovarian stimulation cycles
The same treatment protocol was applied to all oocyte donors during the first 4 days of stimulation. Hence, the differences in the early ovarian response only reflected inter-individual variability. Nevertheless, no apparent relationship was found between residual serum LH activity after the completion of pituitary down-regulation, serum E 2 concentration on day 5 of stimulation and the number of follicles Ͼ8 mm in diameter on day 5 of stimulation, although donors with serum LH ജ1 IU/l before the beginning of stimulation continued with higher LH levels on day 5 of stimulation when compared to donors with initial LH Ͻ1 IU/l, irrespective of the early ovarian response in terms of E 2 production (Table II) .
The first differences between comparable groups of donors with and without LH supplementation (Figures 1 and 2) were observed on day 8 of stimulation. The addition of LH to the stimulation protocol was associated with higher serum E 2 concentrations in donors with initial low serum LH (Ͻ1 IU/l) and low E 2 level on day 5 (Table II) . There was also a trend toward a higher number of follicles of Ͼ8 mm in diameter in groups in which LH was added to the stimulation protocol, but these differences did not reach statistical significance (Table II) . Similar to day 5, LH continued to be higher in all groups of donors in which it was higher before the beginning of stimulation (Table II) . However, no differences in serum LH were detected, either on day 5 or on day 8, between groups of donors in which exogenous LH was added to the stimulation protocol and the corresponding groups of donors stimulated with FSH alone (Table II) .
The peak serum E 2 concentration achieved in the course of ovarian stimulation tended to be higher in all groups in which LH was added to the ovarian stimulation protocol, but the difference from the corresponding group stimulated with FSH alone was significant only in donors with low serum LH before the beginning of stimulation and low E 2 rise on day 5 of stimulation (Table II) . Total FSH dose per stimulated cycle was significantly lower in all groups in which LH was added to the stimulation protocol when compared with corresponding groups of donors stimulated with FSH alone (Table II) .
Oocyte yield and maturity
The number of mature (metaphase II) oocytes per donor was higher in all groups co-stimulated with LH when compared with corresponding groups stimulated with FSH alone (Table III) . The number of immature (germinal vesicles and metaphase I) oocytes was similar in all groups except for groups IVa and IVb, formed by donors with initial LH ജ1 IU/l and receiving exogenous LH as part of the stimulation protocol, in which significantly more immature oocytes were recovered (Table III) .
Fertilization outcomes
The addition of LH to the ovarian stimulation protocol increased the number of normally fertilized, two-pronucleated zygotes (P Ͻ 0.01) in donors with pre-stimulation serum LH Ͻ1 IU/l when compared with corresponding groups stimulated with FSH; this reflected the higher numbers of metaphase II oocytes in these groups rather than an increase in fertilization rate (Table III) . In contrast, the number of normally fertilized zygotes was not different in donors with pre-stimulation LH ജ1 IU/l and stimulated with, or without, the addition of exogenous LH, despite the higher number of metaphase II oocytes in the LH co-stimulated groups (Table III) . This was related to higher rates of abnormal fertilization in the donors with pre-stimulation LH Ͼ1 IU/1 who were co-stimulated with exogenous LH (Table III) .
Zygote and embryo morphology
In the group of donors with low pre-stimulation serum LH, the addition of LH to the ovarian stimulation protocol increased both the number of good-morphology zygotes on day 1 following ICSI and the numbers of cleaving embryos graded as excellent or good on day 3 after ICSI when compared with corresponding groups of donors stimulated with FSH alone (Table IV) . This increase was mainly related to the higher number of normally fertilized oocytes in the groups co-stimulated with LH, because the number of poor-morphology zygotes and that of embryos graded as fair and poor was also slightly but significantly augmented in these groups when compared with corresponding groups of donors stimulated with FSH alone (Table IV) . In contrast, no benefit from exogenous LH addition, in terms of the yield of good-morphology zygotes and embryos, was observed in those groups formed by donors with pre-stimulation serum LH of ജ1 IU/ml (Table IV) . On the contrary, the number of poormorphology zygotes was higher and the number of excellent-3134 morphology cleaving embryos was lower in the groups of donors with pre-stimulation serum LH of ജ1 IU/1 and co-stimulated with exogenous LH when compared with groups of donors with similar characteristics stimulated with FSH alone (Table IV) .
Pregnancy and implantation rates
No differences in pregnancy rates were detected between any comparable groups with and without the inclusion of exogenous LH to the stimulation protocol (Table V) . However, the addition of LH increased the implantation rates in groups of donors with pre-stimulation serum LH of Ͻ1 IU/l and decreased the implantation rates in groups with pre-stimulation serum LH of ജ1 IU/l (Table V) .
Discussion
The present data have shown that the inclusion of exogenous LH in the ovarian stimulation protocol in young, healthy, normogonadotrophic women has different, and even opposing effects on the production of developmentally competent oocytes in different individuals, mainly depending on the individually variable degree of pituitary LH suppression after administration of a long-acting GnRH agonist. In donors in whom serum LH was suppressed to Ͻ1 IU/l, the addition of exogenous LH increased the numbers of developmentally competent oocytes as judged by higher numbers of metaphase II oocytes, of normally fertilized oocytes, and of goodmorphology zygotes and embryos as well as by a higher implantation rate after embryo transfer to recipients prepared by using an invariable protocol. In contrast, in donors in whom residual serum LH after pituitary down-regulation was ജ1 IU/l the addition of exogenous LH to the ovarian stimulation protocol decreased the number of developmentally competent oocytes even though the total oocyte yield was increased. A clue to the understanding of this apparent discrepancy can be found in the dynamics of follicular recruitment during stimulation. According to the protocol of this study, all donors received the same treatment during the first 4 days of stimulation. Hence, day 5 cycle characteristics reflected the individual variability of the ovarian response. On day 8, when consequences of the differences in the ovarian stimulation protocol in different groups could be appreciated, donors with initially low serum LH and receiving exogenous LH had higher serum E 2 concentration and more follicles of Ͼ8 mm in diameter when compared with those stimulated with FSH alone. Because more metaphase II oocytes, normally fertilized oocytes, good-morphology zygotes and embryos and implanted embryos were obtained in those donors with pre-stimulation serum LH of Ͻ1 IU/l who were co-stimulated with exogenous LH, it is evident that some of the follicles recruited between days 5-8 were still capable of yielding developmentally competent oocytes. In contrast, follicles newly recruited between days 5-8 in donors with pre-stimulation serum LH level of ജ1 IU/l and costimulated with exogenous LH were mostly developmentally incompetent because the numbers of mature oocytes, normally fertilized oocytes, good-morphology zygotes and embryos, and the implantation rate were not increased when compared with donors stimulated with FSH alone.
In the groups of donors with low pre-stimulation serum LH levels, serum LH showed a further decrease during the first 5 days of stimulation. Under these conditions, some healthy small antral follicles may fail to be recruited; such follicles may thus be 'rescued' by the subsequent addition of exogenous LH, although this exogeneous LH contribution was not reflected by a measurable increase in serum LH. Rescue of IVF cycles in pituitary down-regulated normogonadotrophic young women with a poor initial response to rFSH has been reported (De Placido et al., 2001 . These data are similar to the observations of this study concerning oocyte donors with a low pre-stimulation serum FSH level. In a previous randomized comparative study dealing with the effects of highly purified FSH versus hMG in an oocyte donation programme (Söderström-Anttila et al., 1996) , using a similar pituitary down-regulation protocol as that applied in the present study, oocytes from donors stimulated with hMG also showed a higher fertilization rate when compared with oocytes from donors stimulated with FSH alone. In our study we could not confirm this observation. This may be caused by the different technique of assisted reproduction used, namely 3135 ICSI in our study and conventional IVF in a previous study (Söderström-Antilla et al., 1996) .
In the groups of donors with pre-stimulation LH level of ജ1 IU/l, the addition of exogenous LH commencing on day 5 of stimulation also led to further follicular recruitment. However, these groups showed a higher degree of previous follicular recruitment during the first 5 days of stimulation, and this initial wave may have involved most, if not all, of the healthy follicles available in the present cycle. The late recruitment between days 5-8 of stimulation may thus mainly concern developmentally incompetent follicles in these donor groups. This would explain why the addition of exogenous LH in donors with initially high serum LH level did not improve the yield of developmentally competent oocytes and embryos.
The addition of exogenous LH in donors with initially high LH levels impaired the oocyte and embryo quality and decreased the implantation rate, although the latter was not significant. This latter observation cannot be explained by the late recruitment of developmentally incompetent follicles, and some of the originally recruited healthy follicles are likely to have deteriorated during subsequent ovarian stimulation of these donors to a higher degree than follicles in the corresponding groups of donors stimulated with FSH alone. It is possible that the strong stimulation of theca interna cells by the conjoint action of endogenous and exogenous LH in the mid-follicular phase of these donors may have led to excess androgen production in some follicles, whose granulosa cell compartment did not produce sufficient aromatase activity to efficiently convert this excess androgen to estrogen. This might lead to a shift of the intrafollicular androgen-to-estrogen ratio in favour of androgen. Under in-vitro conditions, estradiol has been shown to improve cytoplasmic maturation and early post-fertilization development of human oocytes (Tesarik and Mendoza, 1995) , whereas androstenedione irreversibly blocked the estradiol effects (Tesarik and Mendoza, 1997) . It is possible that relative over-production of androgens in vivo may have a similar effect, although no direct experimental evidence for this has yet been provided.
These data support the concept of a 'window' for LH requirement in ovarian follicular development, originally for-mulated by Hillier, according to which there is not only a threshold requirement for LH but also a ceiling level beyond which LH might be deleterious to ovarian stimulation (Hillier, 1994) . It is noteworthy that the poor embryo quality was detected as early as the pronuclear zygote stage. Thus, similar to paternal effects (Tesarik et al., 2002) , maternal, oocyteborne effects on human embryo development also became manifest as early as the first cell cycle after fertilization.
The present data, obtained in an oocyte donation programme, may help the understanding of some discrepancies between previously published studies of which some claimed (Filicori, 1999; Filicori et al., 1999; Fleming et al., 2000; Westergaard et al., 2000 Westergaard et al., , 2001 De Placido et al., 2001; Meo et al., 2002) and others negated (Balasch et al., 1996 (Balasch et al., , 2001 ) effects of exogenous LH on ovarian stimulation outcomes. First of all, the combination of norethisterone and a depot GnRH agonist preparation, used in this study for pituitary down-regulation of oocyte donors, strongly suppresses endogenous LH levels when compared with protocols using a shorter treatment with short-acting GnRH agonist preparations only. Hence, the effect of exogenous LH supplementation may be more perceptible on this strongly suppressed background as compared with studies using milder down-regulation schemes. Furthermore, the effect of LH on oocyte quality is likely to be less perceptible in those groups of patients undergoing IVF with their own oocytes when compared with oocyte donation. For instance, strong response to ovarian stimulation, leading to the production of numerous good-quality oocytes, may be deleterious to uterine receptivity (Paulson et al., 1990; Simon et al., 1998) . Finally, the relative paucity of embryos with high implantation potential, strongly perceived in an oocyte donation programme where embryos from a single donor are shared by several recipients, may escape attention in IVF with the patient's own oocytes where only a few embryos with the best quality are selected for transfer.
When only the impact on oocyte number and developmental competence is taken into account, this study suggests that exogenous LH during ovarian stimulation can be beneficial in some women and detrimental in others. The level of serum LH before the beginning of stimulation or on day 5 of stimulation may become a useful criterion to distinguish between these two conditions, but the optimal cut-off values still remain to be determined.
When extrapolating these findings to poor-responder management, the inclusion of exogenous LH can be expected to increase oocyte yield but should be used with caution to avoid the deterioration of oocyte quality. In good responders, the risk of the development of severe ovarian hyperstimulation syndrome and of deterioration of uterine receptivity by excessive serum E 2 levels must also be taken into account.
